Immunotherapy for Advanced HCC: Current Options and Expert Answers to Clinician Questions

In this episode, David Kaplan, MD, MSc, and Thomas Karasic, MD, review approved immunotherapy options for advanced HCC and answer key questions surrounding use of immune checkpoint inhibitors, with topics including:Current systemic therapy standards of care for patients with advanced HCCUse of single-agent immune checkpoint inhibitor therapy in the first-line settingAssessing bleeding riskUsing immunotherapy in patients with active HBV or HCV infectionsPresenters:David Kaplan, MD, MScAssociate ProfessorPerelman School of MedicineUniversity of PennsylvaniaDirector of HepatologyCorporal Michael J. Crescenz VA Medical CenterPhiladelphia, PennsylvaniaThomas Karasic, MD  Assistant Professor of MedicineDepartment of Hematology-OncologyUniversity of PennsylvaniaPhiladelphia, Pennsylvania Content based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group.Link to full program:https://bit.ly/39V6s72 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.